Abstract
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.
Original language | English |
---|---|
Pages (from-to) | 1568-1570 |
Number of pages | 3 |
Journal | AIDS (London, England) |
Volume | 17 |
Issue number | 10 |
DOIs | |
Publication status | Published - Jul 4 2003 |
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy